Last reviewed · How we verify
veverimer daily
At a glance
| Generic name | veverimer daily |
|---|---|
| Sponsor | Tufts Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia (PHASE1)
- Long-term Safety Extension to Study TRCA-301 (PHASE3)
- Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease (PHASE3)
- Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- veverimer daily CI brief — competitive landscape report
- veverimer daily updates RSS · CI watch RSS
- Tufts Medical Center portfolio CI